PDCD1 and glioma: In addition, the clinical significance of CMTM6 is further confirmed in head and neck squamous cell carcinoma, glioma, and gastric cancer.49–51 CMTM6 expression refines the prognostic value of PD-L1 in pancreatic cancer, and PD-L1high CMTM6high is associated with the worst prognosis, with a 27% 2-year overall survival.52 Although these results underline the therapeutic potential of CMTM6 as a promising target in combination with PD-1/PD-L1 blockade therapy, the targetability of CMTM6 is still largely unknown, indicating that the regulatory mechanism itself needs to be further investigated.